Skip to main content
← All trials
AsthmaLungs and breathingDrugPhase 2

What this study is

This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.

The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.

What's being tested

  • Lunsekimig

    Intervention · DRUG

    * Pharmaceutical form: Solution for injection in vial or pre-filled syringe (PFS) * Route of administration: Subcutaneous injection

Study details

Official title
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301
Sponsor
Sanofi
Conditions
Asthma
Enrolling
900 people
Starts
2024-09-30
Est. completion
2031-01-20
Design
Open-label, single group, Phase 2
Record
View on ClinicalTrials.gov ↗